TONIX PHARMACEUTICALS HOLDIN (TNXP) Stock News

USA - NASDAQ:TNXP - US8902608392 - Common Stock

18.62 USD

+0.56 (+3.1%)

Last: 10/31/2025, 8:16:40 PM

18.56 USD

-0.06 (-0.32%)

After Hours: 10/31/2025, 8:16:40 PM

Technical Analysis

Fundamental Analysis

Analyst Ratings

Earnings Estimates

TNXP Latest News, Press Relases and Analysis

All

Press Releases

6 days ago - By: Tonix Pharmaceuticals Holding Corp.

Tonix Pharmaceuticals Presented Data on Tonmya™ (Cyclobenzaprine HCl Sublingual Tablets) at the 2025 American College of Rheumatology (ACR) Convergence

11 days ago - By: Tonix Pharmaceuticals Holding Corp.

Tonix Pharmaceuticals Announces First Patient Dosed in the Investigator-Initiated FOCUS Study of Tonix’s Intranasal Potentiated Oxytocin in AVP-D Conducted by Massachusetts General Hospital

12 days ago - By: Tonix Pharmaceuticals Holding Corp.

Tonix Pharmaceuticals to Present Poster on Tonmya™ at the 2025 American College of Rheumatology (ACR) Convergence

16 days ago - By: Tonix Pharmaceuticals Holding Corp.

Tonix Pharmaceuticals Presented Data on TNX-801 Mpox Vaccine at World Vaccine Congress–Europe 2025

24 days ago - By: Tonix Pharmaceuticals Holding Corp.

Tonix Pharmaceuticals to Present and Participate in Panel Discussion at World Vaccine Congress, Europe 2025

3 months ago - By: Stocktwits - Mentions: UWM IWMW

News Image

This Pharma Stock Shot Up 4% Pre-Market After FDA Approval For Drug, Retail’s Super Bullish But Believes ‘This Is A Marathon, Not A Sprint’

3 months ago - By: Stocktwits

News Image

Tonix Pharma Scores Best Day Since March On Hopes For First New Fibromyalgia Drug Approval in 16 Years; Retail’s Optimistic

a month ago - By: Tonix Pharmaceuticals Holding Corp.

Tonix Pharmaceuticals Further Strengthens Commercial Leadership Team with Appointment of Ganesh Kamath as Head of Market Access

a month ago - By: Tonix Pharmaceuticals Holding Corp.

Tonix Pharmaceuticals Plans to Initiate Prader-Willi Syndrome Phase 2 Trial of TNX-2900 (Intranasal Potentiated Oxytocin) in 2026

a month ago - By: Tonix Pharmaceuticals Holding Corp.

Tonix Pharmaceuticals Announces Positive Pre-IND Meeting with FDA for TNX-102 SL for the Treatment of Major Depressive Disorder

2 months ago - By: Tonix Pharmaceuticals Holding Corp.

Tonix Pharmaceuticals Announces In-licensing Phase 2/3-Ready Monoclonal Antibody Designed for Seasonal Prevention of Lyme Disease (TNX-4800)

2 months ago - By: Benzinga - Mentions: FN AGRO XNET PGEN ...

Fabrinet, Adecoagro And Other Big Stocks Moving Lower In Tuesday's Pre-Market Session

3 months ago - By: Benzinga - Mentions: PPCB GDRX RSKD EMPD ...

Crude Oil Moves Higher; US Homebuilder Sentiment Declines In August

3 months ago - By: Tonix Pharmaceuticals Holding Corp.

Tonix Pharmaceuticals Announces FDA Approval of Tonmya™ (cyclobenzaprine HCl sublingual tablets) for the Treatment of Fibromyalgia

3 months ago - By: Tonix Pharmaceuticals Holding Corp.

Tonix Pharmaceuticals Reports Second Quarter 2025 Financial Results and Operational Highlights

3 months ago - By: Tonix Pharmaceuticals Holding Corp.

Tonix Pharmaceuticals Announces the Launch of the “Move Fibro Forward” Campaign to Bring Awareness to Individuals Impacted by Fibromyalgia

4 months ago - By: Tonix Pharmaceuticals Holding Corp.

Tonix Pharmaceuticals Announces Presentation of New Data on Mpox and Smallpox Vaccine Candidate TNX-801 at the Vaccine Congress 2025

4 months ago - By: Tonix Pharmaceuticals Holding Corp.

Tonix Pharmaceuticals Announces On-line Publication of Phase 3 RESILIENT Trial Results of TNX-102 SL for Fibromyalgia in the Peer Reviewed Journal, Pain Medicine

4 months ago - By: Tonix Pharmaceuticals Holding Corp.

Tonix Pharmaceuticals Announces Oral Presentation on Mpox and Smallpox vaccine candidate TNX-801 at the Vaccine Congress 2025

4 months ago - By: Tonix Pharmaceuticals Holding Corp.

Tonix Pharmaceuticals Announces Peer-Reviewed Publication in Cancer Cell Journal Highlighting Positive Preclinical Data of mTNX-1700 in Gastric Cancer Animal Models

4 months ago - By: Tonix Pharmaceuticals Holding Corp.

Tonix Pharmaceuticals Announces Inclusion in the Russell 3000® and Russell 2000® Indexes